Form 8-K - Current report:
SEC Accession No. 0001193125-22-170659
Filing Date
2022-06-09
Accepted
2022-06-09 08:08:02
Documents
14
Period of Report
2022-06-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d368092d8k.htm   iXBRL 8-K 24339
2 EX-99.1 d368092dex991.htm EX-99.1 21856
6 GRAPHIC g368092g0609125526193.jpg GRAPHIC 4551
  Complete submission text file 0001193125-22-170659.txt   181017

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20220609.xsd EX-101.SCH 2862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20220609_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20220609_pre.xml EX-101.PRE 11265
8 EXTRACTED XBRL INSTANCE DOCUMENT d368092d8k_htm.xml XML 3416
Mailing Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 221004963
SIC: 2834 Pharmaceutical Preparations